Caseware UK (AP4) 2024.0.164 2024.0.164 2025-02-282025-02-28falsetrue2024-03-01falseNo description of principal activity21The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 08414523 2024-03-01 2025-02-28 08414523 2023-03-01 2024-02-29 08414523 2025-02-28 08414523 2024-02-29 08414523 c:Director1 2024-03-01 2025-02-28 08414523 d:MotorVehicles 2024-03-01 2025-02-28 08414523 d:MotorVehicles 2025-02-28 08414523 d:MotorVehicles 2024-02-29 08414523 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 08414523 d:FurnitureFittings 2024-03-01 2025-02-28 08414523 d:FurnitureFittings 2025-02-28 08414523 d:FurnitureFittings 2024-02-29 08414523 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 08414523 d:ComputerEquipment 2024-03-01 2025-02-28 08414523 d:ComputerEquipment 2025-02-28 08414523 d:ComputerEquipment 2024-02-29 08414523 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 08414523 d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 08414523 d:CurrentFinancialInstruments 2025-02-28 08414523 d:CurrentFinancialInstruments 2024-02-29 08414523 d:CurrentFinancialInstruments d:WithinOneYear 2025-02-28 08414523 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-29 08414523 d:ShareCapital 2025-02-28 08414523 d:ShareCapital 2024-02-29 08414523 d:RetainedEarningsAccumulatedLosses 2025-02-28 08414523 d:RetainedEarningsAccumulatedLosses 2024-02-29 08414523 c:FRS102 2024-03-01 2025-02-28 08414523 c:AuditExemptWithAccountantsReport 2024-03-01 2025-02-28 08414523 c:FullAccounts 2024-03-01 2025-02-28 08414523 c:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 08414523 e:PoundSterling 2024-03-01 2025-02-28 iso4217:GBP xbrli:pure

Registered number: 08414523










VAKHARIA MEDICAL LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 28 FEBRUARY 2025

 
VAKHARIA MEDICAL LIMITED
 

CONTENTS



Page
Accountants' report
 
 
1
Balance sheet
 
 
2
Notes to the financial statements
 
 
3 - 7


 
VAKHARIA MEDICAL LIMITED
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF VAKHARIA MEDICAL LIMITED
FOR THE YEAR ENDED 28 FEBRUARY 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Vakharia Medical Limited for the year ended 28 February 2025 which comprise the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW)we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation.

This report is made solely to the director of Vakharia Medical Limited in accordance with the terms of our engagement letter dated 20 November 2019Our work has been undertaken solely to prepare for your approval the financial statements of Vakharia Medical Limited and state those matters that we have agreed to state to the director of Vakharia Medical Limited in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Vakharia Medical Limited and its director for our work or for this report. 

It is your duty to ensure that Vakharia Medical Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Vakharia Medical Limited. You consider that Vakharia Medical Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of Vakharia Medical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  


BAGINSKY COHEN
CHARTERED ACCOUNTANTS
930 HIGH ROAD
LONDON
N12 9RT
14 November 2025
Page 1

 
VAKHARIA MEDICAL LIMITED
REGISTERED NUMBER: 08414523

BALANCE SHEET
AS AT 28 FEBRUARY 2025

28 February
28 February
29 February
29 February
2025
2025
2024
2024
Note
£
£
£
£

FIXED ASSETS
  

Tangible assets
 4 
16,560
18,604

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
29,060
7,445

Cash at bank and in hand
 6 
93,886
59,145

  
122,946
66,590

Creditors: amounts falling due within one year
 7 
(27,369)
(25,487)

NET CURRENT ASSETS
  
 
 
95,577
 
 
41,103

  

NET ASSETS
  
112,137
59,707


CAPITAL AND RESERVES
  

Called up share capital 
  
1,000
1,000

Profit and loss account
  
111,137
58,707

  
112,137
59,707


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 14 November 2025.



H. N. VAKHARIA
Director

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
VAKHARIA MEDICAL LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1.ACCOUNTING POLICIES

 
1.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 2).

The following principal accounting policies have been applied:

 
1.2

REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
VAKHARIA MEDICAL LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1.ACCOUNTING POLICIES (CONTINUED)

 
1.3

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
1.4

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
25%
Fixtures and fittings
-
25%
Computer equipment
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
1.5

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
1.6

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.7

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
VAKHARIA MEDICAL LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1.ACCOUNTING POLICIES (CONTINUED)

 
1.8

DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


2.



JUDGMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company's accounting policies, which are described in note 1, management is required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from those estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 2 (2024 - 1).

Page 5

 
VAKHARIA MEDICAL LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

4.


TANGIBLE FIXED ASSETS







Motor vehicles
Fixtures and fittings
Computer equipment
Total

£
£
£
£



COST OR VALUATION


At 1 March 2024
19,000
721
7,514
27,235


Additions
-
1,082
3,690
4,772



At 28 February 2025

19,000
1,803
11,204
32,007



DEPRECIATION


At 1 March 2024
4,750
361
3,521
8,632


Charge for the year on owned assets
3,563
451
2,801
6,815



At 28 February 2025

8,313
812
6,322
15,447



NET BOOK VALUE



At 28 February 2025
10,687
991
4,882
16,560



At 29 February 2024
14,250
361
3,993
18,604


5.


DEBTORS

28 February
29 February
2025
2024
£
£


Trade debtors
1,230
-

Other debtors
25,847
5,419

Prepayments and accrued income
1,983
2,026



6.


CASH AND CASH EQUIVALENTS

28 February
29 February
2025
2024
£
£

Cash at bank and in hand
93,886
59,145


Page 6

 
VAKHARIA MEDICAL LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

7.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

28 February
29 February
2025
2024
£
£

Corporation tax
14,145
8,998

Other creditors
10,494
14,265

Accruals and deferred income
2,730
2,224

27,369
25,487



Page 7